{"disease":{"id":"acute-lymphoid-leukemia-disease","name":"Acute lymphoid leukemia, disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"cyclophosphamide","indication_name":"Acute lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"cyclophosphamide","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Tumor cell DNA","drug_class":"Alkylating agent","quality_score":10,"revenue":"1000.0","mechanism":"Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites."},{"drug_id":"cyclophosphamid","indication_name":"Acute lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclophosphamid","company_name":"Zhejiang University","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1200796","indication_name":"Acute lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"CYCLOPHOSPHAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"cyclophosphamide","quality_score":10,"revenue":null,"mechanism":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05348889","title":"First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Chimagen Biosciences, Ltd","has_results":false}],"total":1},"guidelines":[{"drug_id":"cyclophosphamide","guideline_body":"FDA label","recommendation":"Cyclophosphamide is indicated for the treatment of acute monocytic leukemia.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null},{"drug_id":"cyclophosphamide","guideline_body":"FDA label","recommendation":"Cyclophosphamide is indicated for the treatment of acute lymphoid leukemia.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null},{"drug_id":"cyclophosphamide","guideline_body":"FDA label","recommendation":"Cyclophosphamide is indicated for the treatment of acute myelogenous leukemia.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null},{"drug_id":"cyclophosphamide","guideline_body":"FDA label","recommendation":"Cyclophosphamide is indicated for the treatment of adenocarcinoma of the ovary.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null},{"drug_id":"cyclophosphamide","guideline_body":"FDA label","recommendation":"Cyclophosphamide is indicated for the treatment of Burkitt's lymphoma.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null},{"drug_id":"cyclophosphamide","guideline_body":"FDA label","recommendation":"Cyclophosphamide is indicated for the treatment of carcinoma of the breast.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null},{"drug_id":"cyclophosphamide","guideline_body":"FDA label","recommendation":"Cyclophosphamide is indicated for the treatment of chronic lymphoid leukemia.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null},{"drug_id":"cyclophosphamide","guideline_body":"FDA label","recommendation":"Cyclophosphamide is indicated for the treatment of chronic myeloid leukemia (usually ineffective in acute blastic crisis).","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null},{"drug_id":"cyclophosphamide","guideline_body":"FDA label","recommendation":"Cyclophosphamide is indicated for the treatment of histiocytic lymphoma.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null},{"drug_id":"cyclophosphamide","guideline_body":"FDA label","recommendation":"Cyclophosphamide is indicated for the treatment of Hodgkin's disease (Stages III and IV of the Ann Arbor staging system).","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}